Annual report pursuant to Section 13 and 15(d)

Deferred Royalty Obligation related to the Sale of Future Royalties - Additional Information (Details)

v3.24.1
Deferred Royalty Obligation related to the Sale of Future Royalties - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2023
Deferred Royalty Obligation [Line Items]    
Percentage of interest rate amortize liability   17.00%
Non-cash interest expense on deferred royalty obligation   $ 12,570
Blackstone Life Sciences    
Deferred Royalty Obligation [Line Items]    
Upfront payment received $ 140,000 140,000
Blackstone Life Sciences | Maximum    
Deferred Royalty Obligation [Line Items]    
Milestone payment receivable 250,000 $ 250,000
2015 License Agreement | Blackstone Life Sciences    
Deferred Royalty Obligation [Line Items]    
Transaction costs incurred $ 3,800  
2015 License Agreement | Blackstone Life Sciences | Royalty    
Deferred Royalty Obligation [Line Items]    
Revenue interest percentage 4.00% 4.00%
Upfront payment received $ 140,000  
Amendment No. 3 to 2015 License Agreement | Vaxcyte | Royalty    
Deferred Royalty Obligation [Line Items]    
Revenue interest percentage   4.00%